Intraperitoneal Insulin Cannot Correct the Hyperlipidemia of CAPD

Abstract

We have investigated the effect of the administration of small doses of intraperitoneal insulin (mean 2.7 ± 1.45 u/L) on the hyperlipidemia associated with continuous ambulatory peritoneal dialysis (CAPD) in nine non-diabetic patients. Despite significant lowering of both fasting (6.21 ± 0.9 → 4.2 ± 0.5 mmoI/L) and postprandial (9.74 ± 1.1 → 7.4 ± 1.06 mmol/L) blood glucose levels, we saw no effect on serum total cholesterol, triglycerides or B lipoproteins.